Patients with atopic dermatitis were at greater risk for serious infection after initiating Janus kinase inhibitors vs Th2 cytokine inhibitors.

Siltuximab effectively treated patients who experienced common adverse events after chimeric antigen receptor T-cell therapy, according to findings published in Blood Advances.Results showed the agent ...

High-parameter flow cytometry of peripheral blood mononuclear cells enabled physicians to treat recalcitrant erythroderma in ...

TOPLINE: Bispecific antibodies (BsAbs) demonstrated a manageable safety profile in patients with non-Hodgkin lymphoma (NHL), with 48% prevalence of all-grade cytokine release synd ...

Simultaneous expansion and activation of both major γδ T cell subsets (Vδ1+ and Vδ2+) leverages both the rapid antigen ...

Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for ...

Proprietary platform represents the first known approach capable of sustained gamma-delta T cell expansion, eliminating target cells with robust potencyINB-619, a next generation gamma-delta TCE targe ...

Janus kinase (JAK) inhibitors look to be a good treatment option for the newly recognized, rare autoimmune disease known as ...

A research team of Peking University (PKU) conducts research of tumor cachexia in a laboratory at PKU in Beijing, capital of ...

Chinese scientists have identified a cytokine produced by tumor cells as the key factor driving irreversible fat loss ...

More cost-effectiveness studies evaluating bispecific antibody or chimeric antigen receptor T-cell therapies are necessary for enhancing care in myeloma and lymphoma.

Researchers have found that specific gut cells, BEST4/CA7+ cells, regulate electrolyte and water balance in response to bacterial toxins that cause diarrhea. Their findings show that these cells ...